DPYD Genetic Testing in Community Cancer Care to Prevent Fluoropyrimidine Toxicity
Official title: CHaMPION-DPYD: A Community-Based Hybrid Type 2 Implementation-Effectiveness Trial of DPYD Genotyping in Patients with Gastrointestinal Cancers
Funded at Wake Forest University Health Sciences · NIH-11340343 · Data updated 2026-11-12
A community-based study will test whether offering DPYD genetic testing before chemotherapy with FP drugs reduces severe side effects and hospitalizations for people with GI cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $282,467 |
| NIH project number | 1R01CA311879-01 |
| Project ID | NIH-11340343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy in community oncology settings.
✕Less likely to help
Patients not receiving fluoropyrimidine-based therapy or those at sites not adopting testing may not benefit.
What this research studies
This project tests a practical approach to using DPYD genotyping in real-world community oncology clinics. It compares a Test Only approach to a Test plus Implementation Strategy across 12 sites to see if broader testing can lower toxicity and related hospital visits. The study uses a cluster-randomized design within the National Cancer Institute Community Oncology Research Program to understand how best to implement DPYD testing in routine care. If successful, it could make pre-treatment genetic testing a standard part of FP-based chemotherapy in community settings.
Why it matters
Potential benefit: If successful, patients may experience fewer severe chemotherapy side effects and fewer hospitalizations.
How similar studies have gone: Preliminary work suggests DPYD testing can reduce toxicity, but this is the first cluster-randomized type 2 implementation trial in community clinics.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Patel, Jai Narendra — Wake Forest University Health Sciences
- Study coordinator: Patel, Jai Narendra
Related research
Other NIH-funded projects on the same topics.
-
Bacterial biosensors to detect and help prevent GI cancers
A team is building living bacterial sensors that could detect colorectal and pancreatic tumors inside the gut and give a clear diagnostic signal.
-
Gastrointestinal cancers: how stem cells and their environment shape cancer growth
A research project at Columbia University Health Sciences studies how stomach, esophagus, and other GI cancers start and evolve by looking at stem cells, nerve signals, and the surrounding tissue.
-
Bacterial biosensors to help detect GI cancers early
A living bacterial sensor is being developed to spot colorectal and pancreatic cancers early inside the GI tract and give a readable diagnostic output.
-
Cell signaling and gene regulation in liver and gastrointestinal cancers
Researchers are looking at how signaling proteins and gene-regulating enzymes like SIRT6 interact to explain why fatty liver disease can turn into liver cancer.
-
Understanding and Improving Chemoradiation Response in Esophagogastric and Pancreatic Cancer
This grant aims to learn why esophagogastric and pancreatic cancers resist standard chemoradiation and to use that knowledge to guide better, biomarker-driven treatments.
-
How stem cells and nearby tissues drive cancers of the stomach, esophagus, colon, and pancreas
Researchers are looking at how stem cells and surrounding tissues, including nerves, change during long-term inflammation and lead to gastrointestinal cancers so people with conditions like gastritis, Barrett's esophagus, colitis, or pancreatitis might benefit from better prevention or early detection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.